Table 3

Numbers (percentages) of participants who experienced adverse events during study

Ramipril group (n=2443)Placebo group (n=2469)
Non-serious adverse events154 (6.3)98 (4.0)
Most frequent:
Cough80 (3.3)21 (0.9)
Hypertension8 (0.3)12 (0.5)
Vertigo8 (0.3)6 (0.2)
Diarrhoea7 (0.3)6 (0.2)
Headache4 (0.2)5 (0.2)
Serious adverse events1055 (43.2)1097 (44.4)
Most frequent:
Inadequate control of diabetes339 (13.9)346 (14.0)
Cardiac failure70 (2.9)72 (2.9)
Atrial fibrillation60 (2.5)48 (1.9)
Hypertension51 (2.1)54 (2.2)
Angina pectoris35 (1.4)61 (2.5)
Adverse events (serious or not) leading to discontinuation of treatment609 (24.9)554 (22.4)